27.00
0.41 (1.54%)
| Previous Close | 26.59 |
| Open | 26.67 |
| Volume | 1,725,981 |
| Avg. Volume (3M) | 1,780,704 |
| Market Cap | 4,450,571,776 |
| Price / Earnings (TTM) | 12.27 |
| Price / Earnings (Forward) | 16.45 |
| Price / Sales | 3.01 |
| Price / Book | 3.11 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2025 - 5 May 2025 |
| Profit Margin | 23.57% |
| Operating Margin (TTM) | 37.84% |
| Diluted EPS (TTM) | 2.20 |
| Quarterly Revenue Growth (YOY) | 13.90% |
| Quarterly Earnings Growth (YOY) | 29.90% |
| Total Debt/Equity (MRQ) | 5.16% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | 439.12 M |
| Levered Free Cash Flow (TTM) | 336.36 M |
| Return on Assets (TTM) | 12.54% |
| Return on Equity (TTM) | 27.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Alkermes plc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.48% |
| % Held by Institutions | 104.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (Deutsche Bank, 92.59%) | Buy |
| Median | 43.00 (59.26%) | |
| Low | 32.00 (Goldman Sachs, 18.52%) | Buy |
| Average | 42.50 (57.41%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 34.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 27 Mar 2025 | 52.00 (92.59%) | Buy | 33.53 |
| 11 Feb 2025 | 40.00 (48.15%) | Buy | 31.96 | |
| RBC Capital | 13 Mar 2025 | 40.00 (48.15%) | Hold | 33.62 |
| Goldman Sachs | 14 Feb 2025 | 32.00 (18.52%) | Buy | 35.89 |
| HC Wainwright & Co. | 13 Feb 2025 | 46.00 (70.37%) | Hold | 36.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Apr 2025 | Announcement | Alkermes to Report First Quarter Financial Results on May 1, 2025 |
| 02 Apr 2025 | Announcement | Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference |
| 01 Apr 2025 | Announcement | Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia |
| 27 Mar 2025 | Announcement | New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder |
| 26 Feb 2025 | Announcement | Alkermes to Participate in Upcoming Investor Conferences |
| 12 Feb 2025 | Announcement | Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2024 and Provides Financial Expectations for 2025 |
| 05 Feb 2025 | Announcement | Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |